Literature DB >> 8222500

The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies.

P Rosenzweig1, S Brohier, A Zipfel.   

Abstract

In contrast to the plethora of publications on placebo effects in patients, very little is known about placebo effects in healthy volunteers during clinical pharmacology studies. We therefore reviewed the adverse events spontaneously reported during placebo administration in 109 double-blind, placebo-controlled studies involving 1228 volunteers. The overall incidence of adverse events in the healthy volunteers during placebo administration was 19%. As expected, complaints were more frequent after repeated dosing (28%) and in elderly subjects (26%). Overall, the most frequent adverse events were headache (7%), drowsiness (5%), and asthenia (4%), with some variation depending on study design and population. In conclusion, these data shed new light on the impact of experimental conditions on the results of safety evaluations in healthy volunteers participating in clinical pharmacology studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222500     DOI: 10.1038/clpt.1993.190

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  Rapid development of tolerance to dipyridamole-associated headaches.

Authors:  J G Theis; G Deichsel; S Marshall
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.

Authors:  Shauna L Hillman; Sumithra J Mandrekar; Brian Bot; Ronald P DeMatteo; Edith A Perez; Karla V Ballman; Heidi Nelson; Jan C Buckner; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  A meta-analytic approach to estimating nocebo effects in neuropathic pain trials.

Authors:  Dimitrios Papadopoulos; Dimos Dimitrios Mitsikostas
Journal:  J Neurol       Date:  2011-08-03       Impact factor: 4.849

4.  The ophthalmologist's office: planning and practice. Patient traffic flow and use of paramedical personnel.

Authors:  H M Byron
Journal:  Int Ophthalmol Clin       Date:  1975

5.  The placebo effect in healthy volunteers: influence of experimental conditions on physiological parameters during phase I studies.

Authors:  P Rosenzweig; S Brohier; A Zipfel
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

6.  The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Authors:  Michelle Carbuto; R Andrew Sewell; Ashley Williams; Kim Forselius-Bielen; Gabriel Braley; Jacqueline Elander; Brian Pittman; Ashley Schnakenberg; Savita Bhakta; Edward Perry; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2011-08-16       Impact factor: 4.530

Review 7.  Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Jiye Kim; Roderick MacDonald; Balaji Reddy; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

8.  Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Ghieth A Kazkaz; Khaled M Abouelkhair; Ali M Bayer; Osama A Elmasri
Journal:  Int J Clin Oncol       Date:  2012-11-21       Impact factor: 3.402

9.  Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer.

Authors:  Maxine de la Cruz; David Hui; Henrique A Parsons; Eduardo Bruera
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

10.  The effect of surface electrical stimulation on swallowing in dysphagic Parkinson patients.

Authors:  Laura W J Baijens; Renée Speyer; Valeria Lima Passos; Walmari Pilz; Nel Roodenburg; Père Clavé
Journal:  Dysphagia       Date:  2012-01-12       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.